

Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)* of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Energy and Commerce

Subcommittee: Health

Hearing Date: 12/08/2021

Hearing Title :

The Future of Biomedicine: Translating Biomedical Research into Personalized Health Care

Witness Name: Leroy E. Hood, PhD, MD

Position/Title: CEO, Phenome Health

Witness Type: Governmental Non-governmental

Are you representing yourself or an organization? Self Organization

If you are representing an organization, please list what entity or entities you are representing:

Phenome Health

FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of the organization(s) or entities.

Phenome Health - Chief Executive Officer
Institute for Systems Biology - Founder and Director

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.

See attached table of relevant grants made to the Institute for Systems Biology over the past 36 months.

Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.

None

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

- I have attached a written statement of proposed testimony.
- I have attached my curriculum vitae or biography.

* Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

(5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.

(B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include— (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing.

(C) The disclosure referred to in subdivision (B)(iii) shall include— (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be made part of the hearing record.



Witness signature



Date

List of relevant federal grants made to ISB over the past 36 months

Grant Title	Payer	Project Dates	ISB Award Amount
Omics Characterization of Combat-Related PTSD: Early Onset and Female Studies	ARO	02/01/21-12/31/21	\$ 225,000
Omics Characterization of Combat-Related PTSD: Early Onset and Female Studies	ARO	02/01/21-01/23/22	\$ 75,000
Prototyping a self-learning digital twin platform for personalized treatment in melanoma patients	DOE	05/01/21-11/01/21	\$ 50,000
Does post-transcriptional control of NLRP3 inflammasome activity impact development of type 1 diabetes?	NIH	05/12/21-04/30/23	\$ 292,384
The Pacific Northwest Consortium for Post-Acute Sequelae of SARS-CoV-2 Infection	NIH	06/09/21-07/08/21	\$ 17,048
A longitudinal systems-level analysis of the human immune response during Lyme disease	DOD	08/01/21-07/31/24	\$ 1,098,000
Liquid biopsy-based toolkits for neoantigen and cognate TCR discovery for cancer immunotherapy	NIH	09/05/21-08/31/24	\$ 1,346,676
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization	NIH	09/16/21-06/30/26	\$ 2,733,780
Cancer Genomics Cloud Resource	NCI	08/31/21-08/30/22	\$ 1,112,737
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment	NIH	09/01/21-03/31/22	\$ 91,500
Cancer Cloud Resource (CGC)	NCI	08/31/20-08/30/21	\$ 1,137,526
Repurposing of cancer therapeutics for treatment of patients with COVID-19 disease	NIH	08/01/20-07/31/21	\$ 183,000
Clinical Sample Collection COVID19 Patients to Align with NIAID National Study	NIH	06/01/20-05/31/22	\$ 441,482
Site Specific Immunophenotyping Assays of COVID19 Patients to Align with NIAID National Study	NIH	06/01/20-05/31/22	\$ 661,549
A systems approach to understanding overall drug response in a heterogeneous tumor-cell population	NIH	02/01/20-01/31/23	\$ 69,306
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries	NIH	01/24/20-01/23/22	\$ 4,614,222
Biomedical Data Translator Development of Autonomous Relay Agent: RTX	NIH	01/23/20-05/31/20	\$ 30,997
DOCKET: accelerating knowledge extraction from biomedical data sets Knowledge Provider	NIH	01/24/20-01/23/21	\$ 62,220
Next Generation Translational Proteomics for Alzheimer's and Related Dementias	NIH	02/15/20-01/31/25	\$ 324,566
Analysis of Immune and Organ Systems Responses in Patients with COVID-19	BARDA	04/01/20-03/31/21	\$ 10,200,000
RCN-UBE Incubator: Networking Systems Biologists with Community College Educator	NSF	12/15/20-11/30/21	\$ 74,897
Metabolic Signatures for Disease Sub-Classification and Target Prioritization in AMP AD	NIH	01/21/19-08/31/19	\$ 530,700
Longevity Consortium: Project Management	NIH	09/30/18-05/31/23	\$ 540,481
Integrative Cancer Imaging Data Commons (ICIDC)	NIH	07/24/19-06/30/20	\$ 738,949
Leveraging Transcriptional Regulatory Networks for Exposure Analysis	NIH	09/01/19-08/31/21	\$ 197,891
An integrated approach to health and longevity enhancing drug target discovery	NIH	09/15/19-08/31/20	\$ 15,000
Convergence Accelerator Phase I (RAISE): A Multi-Scale Open Knowledge Network for Precision Medicine	NSF	09/01/19-05/31/20	\$ 192,000
Modulation of Alzheimer's Disease by Herpes simplex virus infection	NIH	09/01/19-05/31/20	\$ 100,639
Proteogenomic resource for the development of novel markers for Lyme disease	NIH	11/20/18-10/31/20	\$ 522,044